BioMarin Pharmaceutical has appointed Dr. Robert Plenge, a leading expert in genetics and drug discovery, to its Board of Directors effective September 10, 2026. Dr. Plenge brings extensive pharmaceutical industry experience from Bristol Myers Squibb and Celgene, enhancing BioMarin's efforts to expand its pipeline of treatments for rare genetic diseases. This strategic move aims to strengthen BioMarin's research capabilities and accelerate the development of new medicines for patients with rare conditions worldwide.
BioMarin's appointment of Dr. Robert Plenge to its Board of Directors is notable context for readers. For those following the health sector, 50 of 91 US health stocks traded on Pluang rose today. AstraZeneca plc (AZN) gained 1.80% to USD 163.06 as of Sep 14, 2026 18:52 WIB.
Bill Gross, a serial entrepreneur behind over 175 companies, has launched Idealab.ai, a platform using AI to generate and share over 1.2 million business ideas based on real-world problems. The platform aims to lower barriers to entrepreneurship by h...
The Portnoy Law Firm has launched an investigation into Cardinal Infrastructure Group for possible securities fraud following the company's Q2 2026 financial report. Cardinal revealed a decline in its gross profit margin to 10.8%, down from 13.9% the...
AIOS Tech Inc. announced an agreement to acquire SmartCore Holdings Limited in an all-stock transaction valued at approximately $100 million. The deal will issue 33.3 million AIOS shares to SmartCore's sellers, who will hold about 80% of AIOS shares ...
XBiotech announced positive results from the Phase II TASKIN trial, where their antibody vilamakitug combined with standard chemotherapy improved 12-month overall survival to 61.3% in refractory metastatic colorectal cancer patients, surpassing the s...
Proof and Circle Internet Group demonstrated a new system where AI agents can prove the identity of the person they represent using Proof's x401 open identity protocol and pay merchants in USDC via Circle's x402 payment protocol. This innovation addr...
